Insulet Lifts Annual Forecast On Increased Adoption For Insulin Pump Omnipod 5

Insulet Corporation (NASDAQ:PODD) reported second-quarter adjusted earnings of $1.17 per share, beating the consensus of 92 cents.

PODD shares are rallying today. Track live prices here.

The automated insulin delivery technology maker reported sales of $649.1 million, up 32.9% year over year (31.3% in constant currency), beating the consensus of $612.22 million, exceeding the high end of the company’s guidance range of 26% in constant currency.

Total Omnipod revenue of $639 million, up 33.0%, or 31.4% in constant currency.

U.S. Omnipod revenue of $453.2 million, up 28.7%, and International Omnipod revenue of $185.8 million, up 45%, or 38.8% in constant currency

Drug Delivery revenue of $10.2 million.

Also Read: Goldman Sachs Bullish On Dexcom ...